Having trouble accessing articles? Reset your cache.

Combo quest

Why NantKwest led Viracta’s B round

By leading Viracta Therapeutics Inc.’s series B round and forging a partnership for its lead HDAC inhibitor last week, NantKwest Inc. (NASDAQ:NK) took another step toward bolstering its natural killer cell therapy arsenal.

Wicklow Capital,

Read the full 353 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE